RNA Sequencing led to Targeting FLT3 Gene on Chromosome 13 for Receptor Blockage causing REMISSION in Adult Acute Lymphoblastic Leukemia (ALL) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Pfizer’s Kidney Cancer Drug Sutent Effectively caused REMISSION to Adult Acute Lymphoblastic Leukemia (ALL)

Implantable Synchronized Cardiac Assist Device Designed for Heart Remodeling: Abiomed’s Symphony »

RNA Sequencing led to Targeting FLT3 Gene on Chromosome 13 for Receptor Blockage causing REMISSION in Adult Acute Lymphoblastic Leukemia (ALL)

July 10, 2012 by 2012pharmaceutical

Curator: Aviva Lev-Ari, PhD, RN

Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade

http://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/

Posted in Bio Instrumentation in Experimental Life Sciences Research, Bone Disease and Musculoskeletal Disease, CANCER BIOLOGY & Innovations in Cancer Therapy, Chemical Genetics, Computational Biology/Systems and Bioinformatics, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Genome Biology, Personalized and Precision Medicine & Genomic Research | Tagged Chromosome 13, DNA Sequencing, FLT3 receptor blockage, Kidney Cancer Drug Sutent, Pfizer, Remission in ALL, RNA sequencing, Sutent | 1 Comment

One Response

on November 5, 2012 at 2:46 PM | Reply Imatinib (Gleevec) May Help Treat Aggressive Lymphoma: Chronic Lymphocytic Leukemia (CLL) « Pharmaceutical Intelligence

[…] http://pharmaceuticalintelligence.com/2012/07/10/rna-sequencing-led-to-targeting-flt3-gene-on-chromo… […]

Loading...

Leave a ReplyCancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,318 other subscribers
Recent Posts
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: